EA023302B9 - Способ предотвращения или лечения артрита и применение антитела, специфически реактивного к цитруллинированному эпитопу в этом способе - Google Patents

Способ предотвращения или лечения артрита и применение антитела, специфически реактивного к цитруллинированному эпитопу в этом способе

Info

Publication number
EA023302B9
EA023302B9 EA201001865A EA201001865A EA023302B9 EA 023302 B9 EA023302 B9 EA 023302B9 EA 201001865 A EA201001865 A EA 201001865A EA 201001865 A EA201001865 A EA 201001865A EA 023302 B9 EA023302 B9 EA 023302B9
Authority
EA
Eurasian Patent Office
Prior art keywords
preventing
treating
antibody specifically
specifically reactive
treating arthritis
Prior art date
Application number
EA201001865A
Other languages
English (en)
Russian (ru)
Other versions
EA023302B1 (ru
EA201001865A1 (ru
Inventor
Йозеф Мария Хендрик Ратс
Ренато Герард Силвано Хириви
Original Assignee
Модиквест Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Модиквест Б.В. filed Critical Модиквест Б.В.
Publication of EA201001865A1 publication Critical patent/EA201001865A1/ru
Publication of EA023302B1 publication Critical patent/EA023302B1/ru
Publication of EA023302B9 publication Critical patent/EA023302B9/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rehabilitation Therapy (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
EA201001865A 2008-06-04 2009-06-04 Способ предотвращения или лечения артрита и применение антитела, специфически реактивного к цитруллинированному эпитопу в этом способе EA023302B9 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08157547 2008-06-04
EP08171920 2008-12-17
EP09155484 2009-03-18
PCT/EP2009/056862 WO2009147201A2 (en) 2008-06-04 2009-06-04 Anti-inflammatory agents

Publications (3)

Publication Number Publication Date
EA201001865A1 EA201001865A1 (ru) 2011-06-30
EA023302B1 EA023302B1 (ru) 2016-05-31
EA023302B9 true EA023302B9 (ru) 2016-10-31

Family

ID=40943595

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201001865A EA023302B9 (ru) 2008-06-04 2009-06-04 Способ предотвращения или лечения артрита и применение антитела, специфически реактивного к цитруллинированному эпитопу в этом способе

Country Status (16)

Country Link
US (2) US9718877B2 (https=)
EP (1) EP2294086B1 (https=)
JP (1) JP5528436B2 (https=)
KR (1) KR101752499B1 (https=)
CN (1) CN102056944A (https=)
AU (1) AU2009253923B2 (https=)
BR (1) BRPI0913945A2 (https=)
CA (1) CA2726511C (https=)
DK (1) DK2294086T3 (https=)
EA (1) EA023302B9 (https=)
ES (1) ES2652127T3 (https=)
IL (1) IL209741A0 (https=)
NO (1) NO2294086T3 (https=)
PL (1) PL2294086T3 (https=)
WO (1) WO2009147201A2 (https=)
ZA (1) ZA201008727B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2294086T3 (https=) 2008-06-04 2018-02-10
EP2332987A1 (en) 2009-12-10 2011-06-15 ModiQuest B.V. Anti-inflammatory agents directed against citrullinated epitopes
US20110262505A1 (en) 2010-04-22 2011-10-27 Gina Athwal Seaweed-derived cosmetic compositions
EP2402368A1 (en) 2010-07-02 2012-01-04 Toscana Biomarkers S.r.l. Histone citrullinated peptides and uses thereof
EP2527841A1 (en) * 2011-05-25 2012-11-28 Toscana Biomarkers S.r.l. Methods for the diagnosis of rheumatoid arthritis
WO2013105721A1 (ko) * 2012-01-13 2013-07-18 가톨릭대학교 산학협력단 류마티스 관절염 진단 키트
US9347941B2 (en) 2012-01-13 2016-05-24 Catholic University Industry-Academic Cooperation Foundation Diagnosis kit for rheumatoid arthritis
WO2013109185A1 (en) * 2012-01-19 2013-07-25 Vilara Ab Novel antibodies
FR3007411B1 (fr) * 2013-06-21 2015-07-03 Agronomique Inst Nat Rech Anticorps monocatenaire a chaine lourde de camelide dirige contre la chromatine et utilisations
US20160159922A1 (en) * 2013-07-24 2016-06-09 Vilara Ab Novel Antibodies for the Diagnosis and Treatment of Rheumatoid Arthritis
CA2946925C (en) * 2014-05-05 2023-08-15 Noviosmart Method for the serological diagnosis of rheumatoid arthritis.
JP7037940B2 (ja) 2014-12-11 2022-03-17 シトリル べー．フェー． 特発性肺線維症の治療方法
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
CA2984380A1 (en) * 2015-05-05 2016-11-10 The Regents Of The University Of California H3.3 ctl peptides and uses thereof
EP3713966A1 (en) 2017-11-22 2020-09-30 Vacara AB Antibodies to citrullinated proteins
CU24508B1 (es) * 2017-12-29 2021-04-07 Centro De Ingenieria Genetica Y Biotecnologia Biocubafarma Composición farmacéutica que comprende péptido tipo apl
CA3102360A1 (en) * 2018-06-20 2019-12-26 Pharma Foods International Co., Ltd. Novel anti-pad2 antibody
EP3841120B1 (en) * 2018-08-21 2025-09-24 Citryll B.V. Antibodies binding to citrullinated histone 2a and/or 4
KR20240005856A (ko) 2021-05-04 2024-01-12 씨트릴 비.브이. 세포 외 트랩 억제
EP4085973A1 (en) 2021-05-04 2022-11-09 Citryll B.V. Inhibition of eosinophil extracellular traps
EP4442705A1 (en) 2023-04-03 2024-10-09 Citryll B.V. Dosage
GB202318703D0 (en) 2023-12-07 2024-01-24 Citryll B V Diagnostic agent

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028344A2 (en) * 1997-11-28 1999-06-10 Innogenetics N.V. Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment
WO2004078098A2 (en) * 2003-03-07 2004-09-16 London Health Sciences Centre Research Inc. Peptides associated with hla-dr mhc class ii molecules involved in autoimmune diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
NL1004539C2 (nl) 1996-11-15 1998-05-20 Stichting Tech Wetenschapp Peptide afgeleid van een door auto-antilichamen van patiënten met reumatoïde artritis herkend antigeen, antilichaam daartegen en werkwijze voor het detecteren van auto-immuunantilichamen.
CA2391356A1 (en) 1999-12-21 2001-06-28 Innogenetics N.V. Peptides designed for the diagnosis and treatment of rheumatoid arthritis
GB0721605D0 (en) 2007-11-02 2007-12-12 Cancer Rec Tech Ltd Prostrate cancer susceptibility screening
NO2294086T3 (https=) 2008-06-04 2018-02-10

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999028344A2 (en) * 1997-11-28 1999-06-10 Innogenetics N.V. Synthetic peptides containing citrulline recognized by rheumatoid arthritis sera as tools for diagnosis and treatment
WO2004078098A2 (en) * 2003-03-07 2004-09-16 London Health Sciences Centre Research Inc. Peptides associated with hla-dr mhc class ii molecules involved in autoimmune diseases

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CHOY E H S, KINGSLEY G H, PANAYI G S: "Monoclonal antibody therapy in rheumatoid arthritis.", BRITISH JOURNAL OF RHEUMATOLOGY, OXFORD UNIVERSITY PRESS, GB, vol. 37, no. 5, 1 May 1998 (1998-05-01), GB, pages 484 - 490, XP002503054, ISSN: 0263-7103, DOI: 10.1093/rheumatology/37.5.484 *
DATABASE EMBL RAATS J.M.H.: "Homo sapiens partial mRNA for immunoglobulin heavy chain variable region (IGHV gene), clone B8-6", XP002546083 *
DATABASE EMBL RAATS J.M.H.: "Homo sapiens partial mRNA for immunoglobulin heavy chain variable region (IGVH gene), clone A2-2", XP002546081 *
DATABASE EMBL RAATS J.M.H.: "Homo sapiens partial mRNA for immunoglobulin light chain variable region (IGLV gene), clone B8-6 ;", XP002546084 *
DATABASE EMBL RAATS J.M.H.: "Homo sapiens partial mRNA for immunoglobulin light chain variable region (IGVL gene), clone A2-2", XP002546082 *
DUPLAN V, ET AL: "In the rat, citrullinated autologous fibrinogen is immunogenic but the induced autoimmune response is not arthritogenic.", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, WILEY-BLACKWELL PUBLISHING LTD., GB, vol. 145, no. 3, 1 September 2006 (2006-09-01), GB, pages 502 - 512, XP002503055, ISSN: 0009-9104, DOI: 10.1111/J.1365-2249.2006.03168.X *
KLARESKOG LARS, ET AL: "Immunity to citrullinated proteins in rheumatoid arthritis.", ANNUAL REVIEW OF IMMUNOLOGY., ANNUAL REVIEWS INC., US, vol. 26, 1 January 2008 (2008-01-01), US, pages 651 - 675, XP002503053, ISSN: 0732-0582, DOI: 10.1146/annurev.immunol.26.021607.090244 *
O'DELL JAMES R: "Therapeutic strategies for rheumatoid arthritis.", NEW ENGLAND JOURNAL OF MEDICINE, THE - NEJM, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 350, no. 25, 17 June 2004 (2004-06-17), US, pages 2591 - 2602, XP002503052, ISSN: 1533-4406, DOI: 10.1056/NEJMra040226 *
RAATS JOS M H; ET AL: "Recombinant human monoclonal autoantibodies specific for citrulline-containing peptides from phage display libraries derived from patients with rheumatoid arthritis.", JOURNAL OF RHEUMATOLOGY, JOURNAL OF RHEUMATOLOGY PUBLISHING COMPANY., CA, vol. 38, no. 8, 1 August 2003 (2003-08-01), CA, pages 1696 - 1711, XP008098343, ISSN: 0315-162X *
VAN DER HELM-VAN MIL ANNETTE H M, ET AL: "Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis.", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, vol. 7, no. 5, 1 January 2005 (2005-01-01), GB, pages R949 - R958, XP002503056, ISSN: 1478-6354, DOI: 10.1186/AR1767 *

Also Published As

Publication number Publication date
ZA201008727B (en) 2012-01-25
US9718877B2 (en) 2017-08-01
AU2009253923A1 (en) 2009-12-10
CN102056944A (zh) 2011-05-11
CA2726511C (en) 2018-07-10
BRPI0913945A2 (pt) 2016-09-27
EP2294086A2 (en) 2011-03-16
EA023302B1 (ru) 2016-05-31
PL2294086T3 (pl) 2018-02-28
CA2726511A1 (en) 2009-12-10
NO2294086T3 (https=) 2018-02-10
EP2294086B1 (en) 2017-09-13
JP5528436B2 (ja) 2014-06-25
ES2652127T3 (es) 2018-01-31
WO2009147201A3 (en) 2010-01-28
US10703822B2 (en) 2020-07-07
KR101752499B1 (ko) 2017-06-29
US20110243945A1 (en) 2011-10-06
JP2011523555A (ja) 2011-08-18
KR20110015035A (ko) 2011-02-14
DK2294086T3 (en) 2018-01-02
AU2009253923B2 (en) 2014-02-13
IL209741A0 (en) 2011-02-28
EA201001865A1 (ru) 2011-06-30
WO2009147201A2 (en) 2009-12-10
US20170298146A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
EA023302B9 (ru) Способ предотвращения или лечения артрита и применение антитела, специфически реактивного к цитруллинированному эпитопу в этом способе
WO2008154543A3 (en) Methods for treating juvenile idiopathic arthritis
EP3974453A3 (en) Agents and methods for treating diseases that correlate with bcma expression
WO2012149356A3 (en) Anti-cd40 antibodies and methods of use
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2008063213A3 (en) Uses and compositions for treatment of psoriatic arthritis
UA109658C2 (xx) Антитіло проти cgrp
NZ623607A (en) Anti-gcc antibody molecules and related compositions and methods
WO2011130164A3 (en) Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
NZ707086A (en) Anti-cd40 antibodies and methods of use
UA107600C2 (uk) АНТИТІЛО ПРОТИ N3pGlu БЕТА-АМІЛОЇДНОГО ПЕПТИДУ ТА ЙОГО ЗАСТОСУВАННЯ
AU2016219704A1 (en) Anti-Notch1 antibodies
WO2012012695A3 (en) A method for the treatment of obesity
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
CO6630085A2 (es) Tratamiento de artritis reumatoide con combinacion de laquinimod y metotrexato
MX2014004326A (es) Anticuerpos a cd1d.
WO2012170807A3 (en) Anti-pseudomonas psl binding molecules and uses thereof
MY158481A (en) Compositions and methods for treating inflammatory disorders
MX343376B (es) Anticuerpos humanizados que tienen como objetivo el dominio ec1 de cadherina-11 y composiciones y metodos relacionados.
IN2012DN03362A (https=)
GB201109238D0 (en) Antibodies
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
FI20115165A0 (fi) Terapeuttisia ja diagnostisia menetelmiä
WO2013096776A3 (en) Radioactive compositions and methods for their therapeutic use
WO2009108755A3 (en) Pharmaceutical combinations for the treatment of cancer

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

PD4A Registration of transfer of a eurasian patent in accordance with the succession in title